Drug Trial Radar · NCT00015899
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
Last checked: Nov 19, 2026Latest source record: Oct 14, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Jan 2002
Primary completion
Sep 2005
Study completion Mar 2007
Sponsor
- Lead sponsor
- Pediatric Brain Tumor ConsortiumResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors.
Conditions
- Brain and Central Nervous System Tumors
Interventions
lonafarnibDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Toxicities of SCH 66336 in children and adolescents with refractory CNS cancers
- Maximum tolerated dose of SCH 66336Time frame: Four weeks
- Pharmacokinetics of SCH 66336
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UCSF Comprehensive Cancer Center
San Francisco, California
Children's National Medical Center
Washington D.C., District of Columbia
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts
Duke Comprehensive Cancer Center
Durham, North Carolina
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
Texas Children's Cancer Center
Houston, Texas
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.